• ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • LEGAL & INVESTMENT TEAM
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • AIM RULE 26
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US
Vortex “As a clinician, I am excited about accessing the cancer biology of patient’s through CTCs. Vortex’s technology provides the best source of CTCs to aid in the diagnostic and treatment decisions we face every day.” – Dr. Jonathan Goldman, MD, Director of Clinical Trials in Thoracic Oncology, Associate Director of Drug Development at UCLA “Improving CTCs recovery along with high cellular purity while maintaining viability have tremendous value for translational research and clinical diagnostic applications. The VTX-1 holds the potential to revolutionize blood-based diagnostics.” - Pr. Massimo Cristofanilli, MD, FACP, Professor of Medicine, Associate Director of Translational Research and Precision Medicine, Robert H Lurie Comprehensive Cancer Center, Feinberg School of Medicine Wanda J. Cribbs, Lead Gartner Analyst Population Health & Analytics says: "Wanda's recent HRS press release really stands out. Delivering those results and having a client publicly share credit with their vendor is rare and says a lot. We at Gartner will have our eyes on Wanda in 2018"
NSCI (LON) 5,25 GBX
  • ABOUT US
  • OUR TEAM
    • BOARD
    • MANAGEMENT TEAM
    • PORTFOLIO COMPANY CEO’S
    • LEGAL & INVESTMENT TEAM
    • FINANCE
    • SCIENTIFIC ADVISERS
  • PORTFOLIO
    • CORE PORTFOLIO
    • SEED PORTFOLIO
  • INVESTORS
    • RNS ANNOUNCEMENTS
    • REPORTS AND PRESENTATIONS
    • FINANCIAL RESULTS
    • ANALYST COVERAGE
    • AIM RULE 26
    • FUNDRAISING
    • STRATEGIC REVIEW
  • NEWS
  • CONTACT US

ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

Dec 23, 2016
-
ProAxsis
FacebookTweetGoogle+Linkedin
← PREVIOUS POST
ProAxsis gains backing of Innovate UK
NEXT POST →
New CEO appointed to Wanda
News
  • Conclusion of Strategic Review
  • Glycotest Inc. Receives $3 Million Initial Tranche from $10 Million Series A Financing
  • Termination of Formal Sale Process
  • Update on Strategic Review
  • Form 8 (OPD) – NetScientific (Offeree)
INVESTORS
  • Investors
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • AIM Rule 26
  • News
Categories
  • Glycotest
  • Media
  • News
  • PDS Biotechnology
  • ProAxsis
  • RNS Announcements
  • Vortex BioSciences
  • Wanda Health
Archives
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • July 2015
  • June 2015
  • May 2015
  • April 2015
  • March 2015
  • February 2015
  • January 2015
  • December 2014
  • November 2014
  • October 2014
  • September 2014
  • July 2014
  • June 2014
  • May 2014
  • March 2014
  • February 2014
  • September 2013

NetScientific plc

6 Bevis Marks
1st floor, Bury Court
London
EC3A 7BA

Tel: +44 20 3514 1800
www.netscientific.net
info@netscientific.net

  • Investors
  • RNS Announcements
  • Presentations
  • Financial Results
  • Financial Calendar
  • Analyst Coverage
  • Investment Strategy
  • AIM Rule 26
  • News
copyright
Terms of Use
ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis - NetScientific